Is Mounjaro Good for PCOS? What UK Women Should Know (October 2026)

01 · The core answer

Is Mounjaro good for PCOS?

Mounjaro is a reasonable option for women with PCOS who also meet the weight-management criteria, but it is not a PCOS drug. It is licensed for weight management in adults and for type 2 diabetes.¹ Its benefit in PCOS comes from the weight loss it supports, which is already a first-line recommendation for the condition.¹

That distinction matters. Mounjaro does not treat every feature of PCOS, and a PCOS diagnosis alone does not make you eligible. We have written more on this in our guide on whether Mounjaro helps PCOS.

02 · Your next step

Is this relevant to me, and what next?

It is relevant if you have PCOS and your BMI is 30 or above, or between 27 and 30 with at least one weight-related condition. Mention your PCOS and any fertility plans in your consultation, because improving weight can restore ovulation.¹

If you are ready to check suitability, a GPhC-registered prescriber reviews every consultation, and it is free. Start with the Mounjaro pen and consultation, or see our wider weight loss clinic if you are still comparing options.

Related guide: How long is mounjaro good for.

Related guide: Is mounjaro good for inflammation.

03 · Why weight matters in PCOS

Why weight matters in PCOS

Weight loss is a first-line recommendation in PCOS because it can improve insulin resistance, cycles and symptoms.¹ That is the whole reason a weight-management medicine can be relevant. It does not target hormones such as androgens directly.

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹ In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹

The insulin-response effect is why PCOS is often mentioned in the same breath.

04 · What the trial evidence shows

What the trial evidence shows

The main weight-loss evidence comes from adults in general, not women with PCOS specifically. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.²

These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.² Trial averages do not predict your own result, so be wary of anyone who promises specific results.

05 · Fertility, cycles and contraception

Fertility, cycles and contraception

Improving weight can restore ovulation, which is good news for cycles but has a practical consequence.¹ If your periods have been irregular, do not assume you are protected from pregnancy.

Mounjaro can reduce absorption of oral contraceptives because stomach emptying slows.⁷ The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ Discuss contraception with your prescriber before you start. Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly. Our guide on whether Mounjaro is safe with PCOS covers safety questions in more depth.

06 · Diet, protein and exercise

Diet, protein and exercise alongside treatment

Mounjaro is licensed alongside a reduced-calorie diet, so the aim is a sustainable deficit, not a perfect food list.¹ No food is banned. Prioritise protein at each meal, vegetables and fibre, and regular fluids. Many people feel worse after very fatty, fried or very sugary food, and large portions sit heavily because the stomach empties more slowly, so smaller, slower meals work better.

Some of any rapid weight loss comes from lean tissue, and protecting muscle protects your metabolism, strength and appearance. The levers are adequate protein at every meal and resistance exercise, which matters more, not less, as the dose rises and appetite falls.¹

Increased physical activity is part of the licence, not an optional extra. Regular moderate activity such as brisk walking plus resistance work is the evidence-backed pattern, and it also protects against regain if you later stop treatment.¹

07 · Side effects and hydration

Side effects and staying hydrated

Side effects are the same for women with PCOS as for anyone else, and we cover them in our guide to the good and bad side effects of treatment. Most are digestive, and the most common are nausea, diarrhoea, vomiting, constipation and abdominal discomfort. One practical point is hydration. Reduced appetite means less fluid from food, and vomiting or diarrhoea can dehydrate you quickly, which is the main route to the rare kidney problems reported with this class.¹

Keep water within reach, and treat inability to keep fluids down as a contact-your-clinical-team issue. You can report any suspected side effect through the Yellow Card scheme.¹⁹

Supplements sold as natural GLP-1 boosters are not equivalents and are not substitutes for prescribed treatment.¹

08 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

09 · NHS access

NHS access to Mounjaro

Mounjaro is available on the NHS, but access is being phased in over several years.⁶ NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴

Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.